Marshall Wace LLP Raises Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Marshall Wace LLP boosted its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 162.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,122,296 shares of the company's stock after acquiring an additional 694,243 shares during the quarter. Marshall Wace LLP owned 0.17% of Genmab A/S worth $23,422,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in GMAB. Brandywine Global Investment Management LLC purchased a new stake in shares of Genmab A/S during the fourth quarter worth approximately $33,804,000. Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock valued at $10,660,000 after purchasing an additional 508,104 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after buying an additional 394,670 shares in the last quarter. Trexquant Investment LP increased its stake in shares of Genmab A/S by 495.1% in the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock worth $7,929,000 after acquiring an additional 316,089 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new position in shares of Genmab A/S during the 4th quarter valued at about $3,692,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Up 2.0 %

Shares of NASDAQ GMAB traded up $0.41 during midday trading on Thursday, reaching $20.54. 769,063 shares of the stock were exchanged, compared to its average volume of 1,541,786. The company has a market capitalization of $13.59 billion, a P/E ratio of 11.80, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.41. The stock has a 50 day moving average price of $20.51 and a 200-day moving average price of $21.10.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GMAB shares. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.